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Abstract
Background: Brain inflammation has been implicated as a critical mechanism responsible for the progression of
neurodegeneration and characterized by glial cell activation accompanied by production of inflammation-related
cytokines and chemokines. Growing evidence also suggests that metabolites derived from docosahexaenoic acid
(DHA) have anti-inflammatory and pro-resolving effects; however, the possible role of N-docosahexaenoylethanolamine
(synaptamide), an endogenous neurogenic and synaptogenic metabolite of DHA, in inflammation, is largely unknown.
(The term “synaptamide” instead of “DHEA” was used for N-docosahexaenoylethanolamine since DHEA is a widely used
and accepted term for the steroid, dehydroepiandrosterone.) In the present study, we tested this possibility using a
lipopolysaccharide (LPS)-induced neuroinflammation model both in vitro and in vivo.
Methods: For in vitro studies, we used P3 primary rat microglia and immortalized murine microglia cells (BV2) to assess
synaptamide effects on LPS-induced cytokine/chemokine/iNOS (inducible nitric oxide synthase) expression by
quantitative PCR (qPCR) and enzyme-linked immunosorbent assay (ELISA). To evaluate in vivo effects, mice
were intraperitoneally (i.p.) injected with LPS followed by synaptamide, and expression of proinflammatory
mediators was measured by qPCR and western blot analysis. Activation of microglia and astrocyte in the
brain was examined by Iba-1 and GFAP immunostaining.
Results: Synaptamide significantly reduced LPS-induced production of TNF-α and NO in cultured microglia
cells. Synaptamide increased intracellular cAMP levels, phosphorylation of PKA, and phosphorylation of CREB
but suppressed LPS-induced nuclear translocation of NF-κB p65. Conversely, adenylyl cyclase or PKA inhibitors
abolished the synaptamide effect on p65 translocation as well as TNF-α and iNOS expression. Administration of
synaptamide following LPS injection (i.p.) significantly reduced neuroinflammatory responses, such as microglia
activation and mRNA expression of inflammatory cytokines, chemokine, and iNOS in the brain.
Conclusions: DHA-derived synaptamide is a potent suppressor of neuroinflammation in an LPS-induced model, by
enhancing cAMP/PKA signaling and inhibiting NF-κB activation. The anti-inflammatory capability of synaptamide may
provide a new therapeutic avenue to ameliorate the inflammation-associated neurodegenerative conditions.
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Background
Inflammation is a widely accepted common denomin-
ator among various neuropathological processes and has
been implicated as a critical mechanism responsible for
the progression of neurodegenerative disorders including
Parkinson’s disease [1], Alzheimer’s disease [2], and mul-
tiple sclerosis [3] as well as traumatic brain injury [4].
Microglia are resident immune-like glial cells in the cen-
tral nervous system that contribute to neuroinflammation.
Activated microglia secrete proinflammatory cytokines,
chemokines, and oxygen radicals [5], often leading to
the development of cerebral damage under various patho-
logic conditions. Therefore, microglia activation has been
regarded as a strategic target for therapeutic intervention
in brain diseases associated with inflammation.
Docosahexaenoic acid (22:6n-3, DHA), the major poly-
unsaturated fatty acid highly enriched in the brain, is
known to exert neurotrophic and neuroprotective func-
tions [6–8]. DHA was shown to suppress inflammation
in various cells including microglia cells [9–11], suggest-
ing neuroinflammation is one of the multiple target
mechanisms for its neuroprotective action. Recently,
we have demonstrated that N-docosahexaenoylethano-
lamine (synaptamide), an endogenous metabolite of DHA,
potently induces neurogenic differentiation of neural stem
cells (NSC) and promotes neurite growth and synaptoge-
nesis in developing neurons [12, 13]. The synaptamide
effect on neurogenic differentiation was shown to be me-
diated through the cAMP/PKA signaling pathway [12, 14]
which is also an inhibitory target for lipopolysaccharide
(LPS)-induced NF-κB activation leading to inflammation
[15]. Inhibitory effects of this DHA metabolite on in-
flammation has indeed been reported [16–18] and were
shown to be greater compared to its parent compound
DHA [17]. Nevertheless, the potential role of synaptamide
in neuroinflammation has not been explored. In this study,
we investigated the effects of synaptamide on LPS-induced
neuroinflammation in both in vitro and in vivo models,
along with underlying signaling mechanisms. We found
that synaptamide potently inhibits LPS-induced proinflam-
matory cytokine/chemokine production and nuclear trans-
location of NF-κB subunit p65 in microglia cells through
upregulating cAMP/PKA signaling. In vivo administration
of synaptamide significantly suppressed microglia activa-
tion induced by the LPS injection (i.p.) and almost com-
pletely abolished cytokine production in mouse brains. The
anti-neuroinflammatory effects of synaptamide suggest a
potential new therapeutic avenue for inflammation-
related neurodegenerative conditions or brain injury.
Methods
Chemicals and antibodies
Dulbecco’s Modified Eagle Medium/Ham’a F12 (DMEM/
F12 1:1) and bovine calf serum were purchased from Life
Technologies Corporation (Carlsbad, CA, USA). Keto-
conazole, Indomethacin, SQ 22536, H-89, lipopolysac-
charides from Escherichia coli 055:B5 and forskolin
were purchased from Sigma-Aldrich (St. Louis, MO,
USA), and normal goat serum was acquired from
Dako (Carpentaria, CA, USA). Anti-Iba-1 antibody and
anti-glial fibrillary acidic protein (GFAP) antibody were pur-
chased from Wako (Richmond, VA, USA) and Sigma-
Aldrich (St. Louise, MO, USA), respectively. Antibodies to
PKA, CREB, and GAPDH were purchased from Cell
Signaling. Heneicosanoic acid was from Nu-Chek
Prep (Elysian, MN). Butylated hydroxytoluene (BHT),
LY311727, neomycin sulfate, and 10% boron trifluoride-
methanol (BF3/methanol) were from Sigma-Aldrich (St.
Louis, MO). Methyl arachidonyl fluorophosphonate
(MAFP), bromoenol lactone (BEL), and ZLJ-6 were ob-
tained from Cayman Chemical (Ann Arbor, MI). 2-TEDC
was from Tocris Bioscience (Bristol, UK). HPLC grade
water and acetonitrile were from Avantor Performance
Materials (Center Valley, PA). Other solvents, BCA pro-
tein assay kit, and acetic acid were from Fisher Scientific
(Pittsburgh, PA)
Cell culture
Primary microglia cultures were prepared from 3–4-day-
old Wistar rats (Charles River Laboratories) according to
the procedure previously described [19]. Briefly, after
removing the meninges and blood vessels, the forebrain
was dissociated by repeated pipetting in DMEM/F12
(Life Technologies) containing 10 % bovine calf serum
(BCS) and gentamicin and then filtered through a 70-μm
cell strainer. Cells were collected by centrifugation,
resuspended in 10 % BCS DMEM/F12, and cultured in
75-cm2 flasks (Nunc, Roskilde, Denmark) in a humidi-
fied atmosphere of 5 % CO2/95 % air at 37 °C. After
10–14 days, microglia were isolated by shaking the mixed
glia-containing flasks. The floating cells were seeded onto
plastic tissue culture dishes and incubated at 37 °C. The
attached cells were harvested and seeded onto plates for
further experiments. The purity of microglia greater than
90 % was attained consistently (Additional file 1: Figure S1).
BV2 cells, a mouse microglial cell line that was a kind
gift from Dr. Mason (NIEHS, NIH), were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (ATCC)
containing 10 % fetal bovine serum (GIBCO) with 1 %
penicillin/streptomycin (Invitrogen). Microglia or BV2
cells were treated with LPS (Sigma-Aldrich) at a con-
centration of 100 ng/mL or synaptamide at indicated
concentrations.
Animals
C57BL/6J mice were purchased from Charles River
Laboratories (Portage, MI, USA), and FAAH KO mice
were kind gift from Dr. Cravatt’s laboratory. All
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experiments in this study were carried out in accordance
with the guiding principles for the care and use of ani-
mals approved by the National Institute on Alcohol
Abuse and Alcoholism (LMS-HK-13, LMS-HK-41).
Mice 8–12 weeks of age received intraperitoneal (i.p.)
injections of saline or 1.0 mg/kg LPS (E. coli, serotype
055:B5, Sigma) followed by synaptamide (2 or 5 mg/kg).
At 2 h after final injection, mice were deeply anes-
thetized with isoflurane and perfused quickly with
chilled phosphate-buffer saline (PBS) for RNA isola-
tion or chilled PBS containing 4 % paraformaldehyde
for immunostaining.
siRNA transfection
BV2 cells maintained in DMEM containing 10 % FBS
with 1 % penicillin/streptomycin were transiently trans-
fected with SignalSilence PKA C-α small interfering
ribonucleic acid (siRNA) or scrambled control siRNA
(Cell Signaling Technology) at the final concentration of
100 nM using Lipofectamine 2000 (Invitrogen) with
Opti-MEM according to the manufacturer’s protocol.
Immunostaining
BV2 murine microglia cells stimulated with LPS (100 ng/
mL) were fixed with 4 % paraformaldehyde for 30 min at
room temperature, washed with 0.1 M Tris-buffered
solution (pH 7.5, TBS), blocked with 10 % normal goat
serum in TBS containing 0.3 % Triton X-100 at room
temperature for 60 min, and incubated with mouse-anti-
p65 antibody (1:400) at 4 °C overnight. The cells were
washed with TBS and incubated with Alexa Fluor 488-
conjugated secondary antibodies (1:1000, Life Technolo-
gies Corporation) at room temperature for 60 min. To
visualize nuclei, cells were counterstained with 2 μg/mL
4′,6-diamidino-2-phenylindole (DAPI). Finally, the cells
were mounted with 80 % (vol/vol) glycerol, visualized
under a fluorescent microscope (IX81, Olympus Corp.,
Tokyo, Japan), and the image data were processed using
MetaMorph (Molecular Devices, Sunnyvale, CA, USA)
for quantitative information. For staining brain samples,
mice were anesthetized with isoflurane and transcar-
dially perfused with 0.1 M phosphate buffer (PB, pH
7.4) containing 4 % paraformaldehyde (wt/vol), and the
brains were carefully removed. After overnight fixing in
4 % paraformaldehyde solution followed by submerging
in 30 % sucrose solution at 4 °C, the brains were embed-
ded with O.C.T. compound (Tissue-Tek, 4583) medium,
frozen on dry ice, and stored at −80 °C freezer until use.
Coronal sections (30 μm) were prepared using Leica
Cryostat and stored into the cryoprotective solution at
−20 °C. Brain sections at the approximately same pos-
ition from Bregma were immunostained using anti-Iba-
1 (Wako, catalogue number 019-19741) or anti-GFAP
(Sigma, catalogue number G9269) antibody followed by
Alexa fluor-488-conjugated F (ab’) 2 fragment goat
anti-rabbit IgG (Jackson ImmunoResearch labs, catalogue
number 111-546-003).
Cell fractionation
Cells were harvested at 4 °C and lysed, and cytoplasmic
and nuclear extracts were prepared using an NE-PER
nuclear and cytoplasmic extraction reagent kit (Pierce
Biotechnology) as described by the manufacturer. Prote-
ase inhibitors were added (complete mini-protease in-
hibitor cocktail tablets, obtained from Roche Diagnostic,
Meylan, France). Briefly, 10 mg of cells was resuspended
in 50 μL cytoplasmic extraction reagent I (CERI), mixed,
and incubated on ice for 10 min; 2.75 μL of cytoplasmic
extraction reagent II (CERII) was then added, followed
by mixing and incubation on ice for 1 min. The intact
nuclei were pelleted, and the supernatant cytoplasmic
extract was collected. The nuclei were resuspended in
25 μL of ice-cold nuclear extraction reagent (NER),
incubated on ice repeatedly, and centrifuged to obtain
the supernatant containing nuclear proteins. Protein
concentrations were determined using the micro-
bicinchoninic acid (BCA) protein assay kit from Pierce
Biotechnology.
LC/MS for synaptamide measurement
Samples were frozen at −80 °C until analysis. C57
mouse brains, not including cerebellum or olfactory
bulbs, were homogenized on wet ice using a motorized
Teflon pestle homogenizer in 1–2 mL 50 %/50 %
methanol/water containing 25 μg/mL β-hydroxytoluene
(BHT) as an antioxidant and the following phospholip-
ase, cyclooxygenase, lipoxygenase, or fatty acid amide
hydrolase inhibitors: 10 μM BEL, 30 μM MAFP, 50 μM
ZLJ-6, 25 μM 2-TEDC, 500 μM neomycin sulfate, or
200 μM LY311727. The protein content of the homogen-
ate was measured using BCA protein assay kit. Synapta-
mide, d4-synaptamide, and anandamide were determined
as follows. In brief, 300 μL aliquots of homogenate were
brought to 70 % MeOH and spun in a microcentrifuge at
18,000 RCF at 4 °C for 20 min in the presence of either
d4-synaptamide or d4-anandamide as an internal stand-
ard. Supernatants were loaded onto 30 mg Strata-X 33 μm
polymeric reverse phase SPE cartridges (Phenomenex,
Torrance, CA) that had been prewashed with 2 mL
methanol followed by 2 mL water. Columns were then
washed with 10 mL water and N-acyl ethanolamides
eluted with 1.25 mL methanol containing 50 μg/mL BHT.
The eluant was dried under nitrogen and suspended in a
small volume of methanol. Five microliters of the extract
was analyzed by reverse phase HPLC-MS-MS using a
Zorbax Eclipse Plus C18 column (2.1 × 50 mm, 1.8 μm)
(Agilent Technologies, Santa Clara, CA) coupled to a
Q-Exactive mass spectrometer (Thermo Scientific,
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Waltham, MA) operating in the positive ion targeted
MS-MS mode. HPLC solvents contained 0.01 % acetic
acid, and the ternary gradient consisted of two parts: first,
a change from acetonitrile/methanol/water 16.3/30/53.7
to 48.7/15/36.3 in 5 min, followed by a linear gradient to
18.1/68.4/13.5 in 22 min. N-Acyl ethanolamides were
quantitated against the corresponding internal standard
using the ethanolamine fragment.
Western blot analysis
Proteins from cell lysates (50 μg protein) were separated
via SDS–PAGE and electroblotted onto a polyvinylidene
difluoride (PVDF) membrane for 90 min at 100 V at
4 °C. After blocking with 5 % BSA for 60 min in
TBS-T (20 mM Tris–HCl, pH 7.5, 50 mM NaCl, 0.1
% Tween 20), the membrane was incubated overnight
with primary antibodies in 5 % BSA at 4 °C, washed
with TBS-T buffer, and incubated for 60 min in anti-
rabbit or anti-mouse IgG–horseradish peroxidase
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)
secondary antibodies diluted in 5 % BSA (1:3000).
After treating with chemiluminescence reagents (Thermo
Fisher Scientific, Rockford, IL, USA), protein bands were
detected and quantified using a Kodak Gel Logic 440
imaging system with ImageJ software. Unless specified
otherwise, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as the loading control for all
western blotting analyses.
cAMP assay
Cultured microglia (2.5 × 105 cells in 0.5 mL) were treated
with synaptamide for 15 min, and the cAMP level was
determined using cyclicAMP XP® assay kit (Cell Signaling,
Danvers, MA) according to the manufacturer’s protocol.
Briefly, cells were lysed using a lysis buffer including pro-
tease inhibitor cocktail (Cell Signaling), and the cell lysate
was added to the cyclicAMP XP® assay kit to displace
HRP-linked cAMP bound to an anti-cAMP XP® Rabbit
mAb immobilized onto a 96-well plate. After removing
displaced HRP-linked cAMP, HRP substrate TMB was
added and cAMP concentration was measured colorimet-
rically at 450 nm.
RNA isolation and quantitative RT-PCR
Total RNA was extracted using Trizol according to manu-
facturer’s protocol (Invitrogen, UK). RNA was treated with
DNase I to remove any contaminating genomic DNA
(RQ1 RNase-free DNase; Promega). RNA was then
used for cDNA synthesis applying reverse transcription
reagents (Applied Biosystems Inc., Foster City, CA, USA).
Expression of messenger RNA (mRNA) for TNF-α, iNOS,
IL-1β, IL-6, IL-10, CCL2, and GAPDH were measured
via a SYBR green-based real-time RT-PCR assay.
Samples were analyzed in triplicate on an ABI Prism
7900HT sequence detection system and QuantiTect
SYBR Green PCR kit (Qiagen, CA, USA). The amplifica-
tion conditions were 50 °C for 2 min then 95 °C for
15 min, followed by 40 cycles of 95 °C for 15 s and 55 °C
for 30 s. SDS 2.4 software (Applied Biosystems Inc.,
Foster City, CA, USA) was used to calculate the cycle
threshold (Ct) in real-time assays. ΔΔCt was used to
estimate the differential gene expression between
samples (Method 2001 25:402-408). The relative expres-
sion of mRNA was calculated after normalization
to GAPDH mRNA. Primer sequences are indicated
below as a Table.
For mice For rat
TNF-α Forward CCCTCCAGAAAAGACACCATG CAGATGGGCTGTACCTTATC
Reverse GCCACAAGCAGGAATGAGAAG GGTATGAAATGGCAAATCGG
IL-1β Forward CCACCTTTTGACAGTGATGA CTAGTGTGTGATGTTCCCAT
Reverse GAGATTTGAAGCTGGATGCT CCACTTGTTGGCTTATGTTC
IL-6 Forward GTCGGAGGCTTAATTACACA CTTCCCTACTTCACAAGTCC
Reverse TTTTCTGCAAGTGCATCATC TTCCAAGATCTCCCTGAGAA
IL-10 Forward AGCCTTATCGGAAATGATCC TCTACAAGGCCATGAATGAG
Reverse GGGAATTCAAATGCTCCTTG CGGGTGGTTCAATTTTTCAT
CCL2 Forward GGATCGGAACCAAATGAGAT CTACTCATTCACTGGCAAGA
Reverse ATTTACGGGTCAACTTCACA TCTTGAGCTTGGTGACAAAT
iNOS Forward CCTAGTCAACTGCAAGAGAA TGGGTCTTGTTAGCCTAGT
Reverse TTTCAGGTCACTTTGGTAGG TCACCTTGGTAGGATTTGAC
GAPDH Forward CCACTCACGGCAAATTCAAC AGGATACTGAGAGCAAGAGA
Reverse CTCCACGACATACTCAGCAC TTGATGGTATTCGAGAGAAGG
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Nitrate/nitrite assays
The amount of NO produced by cells was indirectly
measured by the formation of nitrate (NO3
−) and nitrite
(NO2
−) (two stable end products of NO) in culture super-
natants. The total amounts of nitrate and nitrite were
determined with a nitrate/nitrite assay kit (Cayman
Chemical Co., Ann Arbor, MI), using the manufacturer’s
protocols. Briefly, supernatant (100 μL) was incubated
with nitrate reductase (20 μL) at room temperature for
1 h, followed by incubation with 100 μL Griess reagent
(1 % sulfanilic acid, 0.1 % naphthyl ethylenediamine
dihydrochloride, 2.5 % phosphoric acid) for 10 min. The
optical density of each sample was analyzed at 540 nm
in a microplate reader with sodium nitrite as a standard.
ELISA assays
Following the stimulation of the cells with LPS and/or
synaptamide, supernatants were collected and assayed
using sandwich ELISA with their well-matched anti-
bodies. TNF-α was detected using ELISA kits (Invitro-
gen Life Technologies, Frederick, MD, USA) according
to the manufacturer’s instructions [20].
Statistical analysis
The results are expressed as means ± SEM for tripli-
cate samples and represent at least three independent
experiments. Statistical analyses were conducted using
one-way ANOVA followed by Tukey’s post hoc test
(Prism software, GraphPad Inc., CA, USA). The statistical
significance was determined at p < 0.05. Means designated
with the same letter are not significantly different.
Results
Synaptamide inhibits LPS-induced TNF-α/iNOS expression
in microglia cells
To characterize the synaptamide effects on neuroinflam-
mation, the LPS-stimulated expression of TNF-α and
iNOS (inducible nitric oxide synthases) were measured
as representative proinflammatory cytokine and nitrogen
species, respectively, at the mRNA and protein/nitrogen
species product levels (Fig. 1), using primary cultures
of rat microglia. After optimization of the LPS dose
(10–1000 ng/mL) and time course (30 min–4 h) for the
induction of proinflammatory cytokine expression (data
not shown), the TNF-α/iNOS expression was evaluated
after stimulation with LPS at 100 ng/mL for 1 h. Primary
microglia cells significantly increased the expression of
TNF-α (17.34 ± 1.83-fold) and iNOS (7.74 ± 0.73-fold)
mRNA relative to the control level. Synaptamide dose-
dependently suppressed LPS-induced TNF-α and iNOS
mRNA expression. After treatment with 1, 10, and 100 nM
synaptamide, LPS-induced TNF-α mRNA expression
Fig. 1 Inhibitory effect of synaptamide on LPS-induced expression of TNF-α and iNOS in microglia cells. Primary rat microglia cells were incubated with
LPS (100 ng/mL) and/or synaptamide at the indicated concentration. Synaptamide was added immediately after LPS exposure. Levels of TNF-α (a) and
iNOS (b) mRNA were determined by qPCR after 1 h incubation. After 24 h, accumulated levels of TNF-α (c) and nitric oxide (d) in the media were measured
by ELISA and Griess reaction. The data represent the mean ± SEM at least three independent experiments. Means designated with the same letter are not
significantly different. One-way ANOVA followed by Tukey’s post hoc test (Prism Software, SigmaStat)
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decreased from 17.34 ± 1.83 (fold increase) to 13.17 ± 1.95,
9.18 ± 1.34, and 6.37 ± 0.97, respectively (Fig. 1a). At these
concentrations, synaptamide also decreased iNOS mRNA
from 7.74 ± 0.73 (fold increase) to 6.09 ± 0.67, 4.37 ± 0.69,
and 2.71 ± 0.39, respectively (Fig. 1b).
At 24 h after LPS treatment, marked increases in
TNF-α protein (31.02 ± 0.52-fold) and nitric oxide
(4.17 ± 0.05-fold) were observed in the rat microglial
culture media, which was reduced by synaptamide
dose-dependently (Fig. 1c, d). The BV2 murine micro-
glia cells also produced similar results as synaptamide de-
creased LPS-induced increase in TNF-α and iNOS mRNA
as well as TNF-α protein and nitric oxide (data not
shown). The in vitro data obtained from these two micro-
glia cultures indicated that synaptamide at nanomolar
concentrations can significantly suppress the production
of proinflammatory cytokine/nitrogen species induced
under a LPS-stimulated condition.
Synaptamide among fatty acyl ethanolamides uniquely
suppresses LPS-induced TNF-α and iNOS expression
We tested whether other fatty acyl ethanolamides such
as arachidonoyl ethanolamine (AEA), oleoyl ethano-
lamide (OEA), and palmitoyl ethanolamine (PEA) exert
similar anti-inflammatory activity. At 10 nM, only synap-
tamide significantly suppressed LPS-stimulated TNF-α
and iNOS mRNA expression in primary microglia
(Fig. 2a, b) and BV2 cells (Fig. 2c, d), suggesting that the
observed inhibitory effect is specific to synaptamide. The
LPS-induced expression of other proinflammatory cyto-
kines such as IL-1β, IL-6, and CCL2 was similarly sup-
pressed only by synaptamide in BV2 cells as shown in
Additional file 1: Figure S4.
Synaptamide decreases LPS-induced TNF-α expression
through cAMP/PKA signaling pathway
Polyunsaturated fatty acids can be oxygenated to lipid
mediators by cyclooxygenase (COX), lipoxygenase (LOX),
and cytochrome P450 enzymes. Some of these metabolites
are known to mediate short- and long-term inflammatory
responses [21]. To investigate whether an oxygenated
form of synaptamide is involved in the suppression of
proinflammatory cytokine production, synaptamide effects
were examined using specific oxygenase inhibitors (Fig. 3a).
We found that 2-TEDC, indomethacin and ketoconazole
(KTZ), specific inhibitors of LOX, COX, and cytochrome
P450, respectively, did not affect the synaptamide-mediated
inhibition of TNF-α expression in murine microglial cells,
suggesting unlikely the involvement of an oxygenated me-
tabolite. We have recently shown that the potent neuro-
genic activity of synaptamide is mediated via PKA/CREB
activation [12]. Previous studies indicated cAMP/PKA/
Fig. 2 Suppression of LPS-induced TNF-α and iNOS expression specific to synaptamide. Cells were incubated with LPS (100 ng/mL) and acylethanolamides
at 10 nM. Acylethanolamides were added immediately after LPS exposure. Levels of TNF-α and iNOS (a, b; rat primary microglial cell, c,
d; BV2 murine microglial cell) mRNA were determined by qPCR after 1 h incubation. The data represent the mean ± SEM at least three
independent experiments. Means designated with the same letter are not significantly different
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Fig. 3 (See legend on next page.)
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CREB signaling attenuates LPS-induced inflammatory
responses by inhibiting NF-κB activation [22, 23]. There-
fore, we tested whether synaptamide ameliorates the
LPS-induced TNF-α and iNOS expression via cAMP/
PKA pathway. Adenylyl cyclase inhibitor (SQ 22536,
10 μM) or PKA inhibitor (H-89, 10 μM) added to the
culture media 30 min prior to LPS and synaptamide
treatment completely blocked synaptamide-derived sup-
pression of TNF-α and iNOS expression (Fig. 3b, c). To
further confirm the role of PKA in synaptamide-mediated
anti-inflammatory effect, cells were transfected with
siRNA against PKA catalytic subunit α and scrambled
control siRNA. Similar to the pharmacological inhibition,
PKA knockdown by siRNA abolished the synaptamide-
mediated expression of TNF-α and iNOS (Fig. 3d, e).
Furthermore, synaptamide at 1–100 nM dose-dependently
increased cellular cAMP production in both primary rat
microglia (2.48 ± 0.37-fold increase at 100 nM, p < 0.032)
(Fig. 3f, upper panel) and BV2 murine microglia cells
(1.86 ± 0.17-fold increase at 100 nM, p < 0.001) (Fig. 3f,
bottom panel). At the indicated concentrations, synapta-
mide also significantly increased phosphorylation of PKA
and CREB in BV2 cells (Fig. 3g). These results indicate
that synaptamide suppressed LPS-induced TNF-α and
iNOS expression through the upregulation of cAMP and
PKA signaling.
Synaptamide inhibits LPS-induced p65 translocation
Previous studies have suggested that NF-κB is an impor-
tant regulator of the TNF-α and iNOS gene expression
[24, 25]. Other studies have also shown that cAMP
inhibits the induction of a distinct set of genes regulated
by NF-κB [22, 26, 27]. Since synaptamide induces cAMP
production in microglia, we examined whether synapta-
mide affects p65 nuclear translocation, a downstream
event of NF-κB activation (Fig. 4). Both immunostaining
data (Fig. 4a) and western blot analysis after nuclear
fractionation (Fig. 4b) consistently confirmed that cyto-
solic p65 translocates to the nucleus following LPS stimula-
tion, and this translocation was markedly prevented by the
addition of 10 nM synaptamide. Furthermore, pretreatment
of BV2 cells with SQ 22536 and H-89 for 30 min abolished
the synaptamide effects on LPS-induced p65 nuclear
translocation, indicating that synaptamide inhibits p65
translocation through activating the cAMP/PKA signaling
pathway. Thus, the suppression of LPS-induced NF-κB ac-
tivation/p65 translocation through cAMP increase and
PKA activation may be associated with the observed in-
hibitory effect of synaptamide on TNF-α and iNOS ex-
pression. A fatty acyl ethanolamide derived from oleic
acid, OEA, showed no effect on p65 nuclear translocation.
Synaptamide suppresses proinflammatory responses in
LPS-challenged mice
The in vivo effect of synaptamide on neuroinflammation
was tested in mice after LPS-challenge (1 mg/kg, i.p.),
an established model of neuroinflammation [28, 29],
followed by i.p. injection of synaptamide (5 mg/kg).
To confirm the synaptamide delivery to the brain, we
made a parallel injection of d4-synaptamide (5 mg/kg, i.p.)
and its level in the brain was evaluated at 30 min and 1 h
after injection (Fig. 5a). At 30 min and 1 h after injection,
d4-synaptamide was detected in the brain at 1.12 ± 0.17
and 0.21 ± 0.02 fmol/μg protein, which was approximately
ten- and two-fold higher than the endogenous synaptamide
level (0.11 ± 0.01 fmol/μg protein), respectively. The en-
dogenous anandamide level (0.10 ± 0.003 fmol/μg protein)
was similar to that of synaptamide. As reported earlier, LPS
administration (1 mg/kg, i.p.) significantly elevated the ex-
pression of proinflammatory genes in the mouse brain
(Fig. 5b). At 2 h after LPS injection, mRNA levels of TNF-
α, IL-1β, IL-6, iNOS, and CCL2 increased 13.48 ± 1.73-,
125.26 ± 13.21-, 91.83 ± 13.43-, 457.11 ± 30.34-, and 95.82
± 10.70-fold, respectively. Subsequent injection of synapta-
mide significantly dampened the LPS-induced increase of
these proinflammatory mediators, as the LPS-induced
mRNA expression of TNF-α, IL-1β, IL-6, iNOS, and CCL2
was decreased by 80.31, 90.80, 83.61, 74.46, and 90.01 %, re-
spectively. In contrast to these proinflammatory mediators,
the anti-inflammatory cytokine IL-10 that was elevated
after the LPS injection was not affected by synaptamide.
Synaptamide inhibits LPS-induced activation of microglia
in the mouse brain
Since activated microglia and astrocytes are known to re-
lease proinflammatory mediators in the brain parenchyma
(See figure on previous page.)
Fig. 3 Involvement of cAMP/PKA signaling in the suppression of LPS-induced TNF-α expression by synaptamide. Microglia cells were incubated with LPS
(100 ng/mL) and 10 nM synaptamide, and levels of TNF-α and iNOS mRNA were determined by qPCR at 1 h after incubation. 5-, 12-, 15-LOX inhibitor
(2-TEDC, 10 μM); COX inhibitor (Indo, 10 μM); P450 inhibitor (KTZ, 10 μM) (a); adenylyl cyclase inhibitor (SQ 22536, 10 μM); and PKA inhibitor (H-89, 10 μM)
(b, c) were added 30 min prior to LPS treatment. BV2 murine microglia cells were transfeted with PKA siRNA or scrambled control RNA for 48 h prior to
the treatment with LPS (100 ng/mL) and synaptamide (10 nM) for 1 h (d, e). Successful knockdown of PKA expression is indicated in the inset. PKA primary
rat microglia (f, upper) and BV2 (f, bottom) cells were treated with synaptamide (1–100 nM) or forskolin (For, 10 μM) as a positive control for 15 min, and
cAMP levels were measured. BV2 cells were incubated with synaptamide at the indicated concentration for 30 min and subjected to immunoblot ana-
lysis using antibodies that specifically recognize phosphorylated and non-phosphorylated PKA, CREB (g). Graph values are mean ± SEM of protein levels
of p-PKA/p-CREB relative to PKA/CREB, respectively (n = 3). Means designated with the same letter are not significantly different
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Fig. 4 (See legend on next page.)
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[30–32], we examined whether synaptamide affects the ac-
tivation of microglia and/or astrocytes. Brain sections
were prepared at 24 h after LPS and synaptamide injec-
tions and immunostained with antibody against microglia
and astrocyte markers Iba-1 and GFAP, respectively. The
number of activated microglia that showed strong Iba-1
signal and enlarged cell body increased at 24 h after LPS
injection in the cerebral cortex and corpus callosum
(Fig. 6a, b). Subsequent synaptamide treatment signifi-
cantly reduced Iba-1 immunoreactivity, compared to mice
injected with LPS alone. In contrast to microglia, LPS at
this dose did not significantly affect astrocyte activation as
(See figure on previous page.)
Fig. 4 Inhibition of LPS-induced p65 translocation by synaptamide. BV2 murine microglia cells were incubated with LPS (100 ng/mL) with or
without synaptamide (10 nM) and OEA (10 nM) for 30 min. Adenylyl cyclase inhibitor (SQ 22536, 10 μM) and PKA inhibitor (H-89, 10 μM) were
added 30 min prior to LPS/synaptamide treatment. Translocation of p65 was determined by immunocytochemistry (red, Alexa Fluor 588; blue,
DAPI) (a). Nuclear levels of p65 were determined by immunoblot analysis. α-Tublin and lamin A/C were used as internal controls for cytosolic
and nuclear fractions (b). Densitometric analysis of the western blots is represented as the mean band density normalized to lamin A/C. Values
are the means ± SEM (n = 3). Means designated with the same letter are not significantly different. In A, the fluorescence intensity profile
across a transverse section of one cell indicated in the second column is shown in the fourth column
Fig. 5 In vivo effect of synaptamide on proinflammatory responses in LPS-challenged mice. The time course of the exogenous synaptamide was
determined by injecting 5 mg/kg (i.p.) d4-synaptamide into C57BL/6 mice (n = 3 for each time point), and brains were collected at indicated time
points for LC/MS analysis (a). C57BL/6 mice (n = 3 for each group) were treated with synaptamide (5 mg/kg, i.p.) following LPS injection (1 mg/kg,
i.p.), and brains were collected at 2 h to determine LPS-induced gene expression by qPCR (b). Values are presented as mean ± SEM from four
mice. Means designated with the same letter are not significantly different
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Fig. 6 Activation of microglia suppressed by synaptamide in the LPS-challenged mouse brain. Brain sections (30-μm thick) were prepared
24 h after LPS and/or synaptamide injection, and immunostaining for Iba-1 and GFAP was performed. Iba-1 (a) and GFAP (c) images from
whole sections (top panel) and higher magnification of the rectangular area (×20, bottom panel) in the cerebral cortex (CX) and corpus
callosum (CC) are presented, along with quantification results of Iba-1 (b) and GFAP (c). The Iba-1 and GFAP protein levels are shown by
the western blot analysis of the whole brain extract (d). Values are presented as mean ± SEM from four mice. Means designated with the
same letter are not significantly different. Scale bar: 100 μm (a, c)
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the GFAP immunoreactivity was not altered after LPS
challenge or by synaptamide treatment (Fig. 6c). Western
blot analysis also indicated that synaptamide significantly
lowered the LPS-induced Iba-1 protein expression without
altering the GFAP level (Fig. 6d).
Synaptamide suppresses proinflammatory responses in
LPS-challenged FAAH KO mice
Synaptamide, as a substrate for fatty acid amide hydro-
lase (FAAH) [13], can be converted to DHA in vivo, and
therefore, the observed anti-inflammatory effect of synap-
tamide may be due to its hydrolysis product DHA. To test
this possibility, anti-inflammatory effects of synaptamide
were examined in FAAH knock-out (KO) mice where
hydrolysis of synaptamide to DHA does not occur (Fig. 7).
The endogenous brain synaptamide level in FAAH KO
mice (0.34 ± 0.04 fmol/μg protein, Fig. 7a) was higher
compared to the level observed in the wild-type (WT)
mice (0.11 ± 0.01 /μg protein, Fig. 5a). Anandamide level
was also higher in FAAH KO (0.29 ± 0.04 fmol/μg protein,
Fig. 7a) compared to WT brains (0.10 ± 0.003 fmol/μg
protein, Fig. 5a). When synaptamide (2 mg/kg, i.p.) was
injected in FAAH KO mice, brain synaptamide at 1 h after
injection increased by 3.5-fold to 1.18 ± 0.02 fmol/μg pro-
tein. Upon injection of LPS (1 mg/kg, i.p.) followed by
synaptamide (2 mg/kg), LPS-induced expression of TNF-
α, IL-1β, IL-6, iNOS, and CCL2 was almost completely
blocked (by 87.01, 97.74, 94.22, 97.03, and 97.06 %, respec-
tively) (Fig. 7b), indicating that synaptamide suppresses the
expression of proinflammatory mediators more potently in
Fig. 7 Suppression of proinflammatory responses by synaptamide in FAAH KO mice. Synaptamide levels in the FAAH KO mouse brains were
quantified by mass spectrometry at 1 h after injection (i.p.) of 2 mg/kg synaptamide (a). The cytokine/chemokine expression in the brain was
determined by qPCR at 2 h after injection of 1 mg/kg LPS followed by 2 mg/kg synaptamide (b). Values are presented as mean ± SEM from
four mice. Means with the same letter are not significantly different
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FAAH KO mice compared to WT. These results esta-
blished that the inhibitory effect of synaptamide on
neuroinflammation does not involve its hydrolysis to
DHA. Interestingly, synaptamide treatment increased
IL-10 expression in the brains of LPS-challenged
FAAH KO, unlike the wild-type case.
Discussion
In this study, we investigated potential inhibitory effects
of synaptamide, a DHA metabolite, on neuroinflamma-
tion using in vitro and in vivo models of LPS-induced
neuroinflammation. The main finding of this study is
that synaptamide potently inhibits LPS-induced proin-
flammatory cytokine expression and oxidative stress
in microglia by upregulating cAMP/PKA signaling and
suppressing NF-κB p65 nuclear translocation. To our
knowledge, this is the first demonstration of the protective
role of synaptamide in LPS-induced neuroinflammation
and the molecular mechanism responsible for the anti-
inflammatory effects.
cAMP is an important intracellular regulator of micro-
glia cell homeostasis and its negative perturbation
through proinflammatory signaling results in microglial
cell activation [33, 34]. Synaptamide was shown to
induce neurogenic differentiation of NSCs [12, 14] and
axon growth [12] by promoting cAMP/PKA signaling.
We found that synaptamide suppresses proinflammatory
cytokine expression also in a cAMP/PKA-dependent
manner in LPS-treated rat and murine microglia cells. It
has been reported that oxygenated forms of synaptamide
block platelet-leukocyte aggregation [18]. For neuro-
inflammation, however, inhibiting COX, LOX, or P450
showed no influence on the synaptamide effects (Fig. 3a).
Rather, inhibiting adenylyl cyclase by SQ 22536 or PKA
by H-89 as well as PKA gene silencing abolished the
synaptamide effects on LPS-induced TNF-α and iNOS
mRNA expression in microglia cells (Fig. 3b–e), indica-
ting that the observed anti-inflammatory effect of synap-
tamide was mediated through cAMP/PKA signaling.
Elevation of intracellular cAMP (Fig. 3f ) along with
increased phosphorylation of PKA and CREB in micro-
glia cells observed after synaptamide treatment (Fig. 3g)
further supports the involvement of cAMP/PKA signal-
ing in amelioration of LPS-induced neuroinflammation
by synaptamide.
LPS activates NF-κB, an important regulator of the
immune responses [35–37], through stimulation of Toll-
like receptors (TLRs). NF-κB activation involves trans-
location of p50/p65 subunits of NF-κB from the cyto-
plasm to the nucleus in most cell types [38]. In microglia,
LPS was shown to activate the NF-κB signaling pathway
via TLR4/MyD88, which in turn promotes transcription of
proinflammatory genes [39]. While LPS induces NF-κB
translocation into the nucleus and its transcriptional
activity [40], activation of cAMP/PKA signaling inhibits
nuclear translocation of NF-κB [22, 23] and negatively
modulates NF-κB transcriptional activity [22, 23, 41]. Our
data indicate significant suppression of LPS-induced NF-
κB p65 nuclear translocation by the cAMP-elevating
metabolite synaptamide in microglia cells. The ability of
synaptamide to activate cAMP/PKC was essential for this
suppression as adenylyl cyclase inhibitor SQ22536, PKA
inhibitor H-89, or PKA gene silencing completely blocked
the observed effect of synaptamide (Fig. 4).
Activated PKA can interact with NF-κB and CREB for
the regulation of gene transcription. Some studies have
indicated that PKA suppresses NF-κB activity by promot-
ing its interaction with CBP and/or p300 [42], while others
have suggested that phosphorylated CREB inhibits NF-κB
activation by blocking the interaction of CBP and NF-κB
complex [43]. Nevertheless, overexpression of CBP and
p300 failed to reverse the PKA-mediated inhibition of p65
[22], suggesting that further studies are needed to unveil
the role of these proteins as well as diverse inflammation-
associated genes regulated by the interaction of CREB,
NF-κB, and synaptamide in future.
The anti-inflammatory effect of synaptamide was
also demonstrated in vivo in the present study using a
systemic LPS administration model. The levels of cyto-
kines, nitric oxide, prostaglandins, and other proin-
flammatory substances in the brain increase in this
model [28, 29, 44–46], shifting the CNS environment
towards a proinflammatory state. Our study also
showed sharp increases in the expression of TNF-α,
IL-1β, IL-6, IL-10, CCL2, and iNOS mRNA after intra-
peritoneal injection of LPS (Figs. 5 and 7). Although
how peripheral endotoxin contributes to neuroinflam-
mation remains unclear, intercommunication between
CNS and peripheral immune systems in response to
endotoxin is apparent. Systemic LPS could induce
brain inflammation through indirect mechanisms such
as altering permeability of the blood-brain barrier
(BBB), enhancing interaction between the BBB and
immune cells [28, 47], or peripheral release of inflam-
matory substances that can cross the BBB [48, 49].
Synaptamide being a lipophilic compound clearly
crossed the BBB (Figs. 5a and 7a) and produced marked
suppression of LPS-induced proinflammatory cytokine/
chemokine expression (Figs. 5b and 7b). At 60 min after
synaptamide injection at a lower dose (2 mg/kg, i.p.), a
significantly higher level of synaptamide (1.18 ± 0.02 fmol/
μg protein) remained in FAAH KO brains (Fig. 7a)
compared to the WT injected at 5 mg/kg, i.p. (Fig. 5a)
(0.21 ± 0.02 fmol/μg protein), indicating that hydrolysis of
synaptamide by FAAH actively occurred. The better
inhibitory outcome after synaptamide injection observed
in the FAAH KO mice was consistent with a higher synap-
tamide level in the KO mouse brain compared to the
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WT brain. These data clearly indicated that the anti-
inflammatory action of synaptamide was most likely pro-
duced by synaptamide itself, not by its hydrolysis to DHA.
Previous studies have indicated some anti-inflammatory
effects of AEA, OEA, and PEA at micromolar concentra-
tions [50, 51]. However, none of these fatty acylethanola-
mides except synaptamide were found to be effective in
suppressing proinflammatory cytokine expression at low
nM concentrations (Fig. 2, Additional file 1: Figure S4).
The potency and specificity of synaptamide demonstrated
in our study suggest the involvement of receptor-mediated
processes. Further studies will be necessary to eluci-
date the definitive receptor signaling that mediates the
anti-inflammatory action of synaptamide.
Recently, it has been reported that it is microglia, not
astrocytes, that produce IL-1β in response to TLR acti-
vation and play a pivotal role in LPS-mediated toxicity
[52, 53]. In line with this report, LPS elicited microglia
activation in vivo without significant induction of astro-
cyte activation (Fig. 6). Both in vivo (Figs. 4, 5, and 6)
and in vitro results (Figs. 1, 2, 3, and 4) from the present
study indicate that synaptamide is a potent regulator of
LPS-induced microglial activation, suggesting microglia
activation as the major target for the regulatory action
of synaptamide on LPS-induced neuroinflammation.
Interestingly, synaptamide exhibited stronger inhibitory
effects in vivo compared to in vitro culture systems. It
is possible that systemically injected synaptamide may
have affected not only the microglia cells in the brain
but also the peripheral immune system. Indeed, our
preliminary results indicated that synaptamide suppresses
LPS-induced TNF-α and IL-1β expression in the plasma
at 2 and 6 h after LPS injection (Additional file 1: Figure
S3). Further systematic evaluation of the synaptamide
effects on peripheral immune responses will help to clarify
the profound in vivo effect of synaptamide.
Conclusions
We have demonstrated in this study that synaptamide, a
DHA-derived endogenous metabolite, exerts potent anti-
inflammatory effects by upregulating cAMP/PKA signal-
ing and inhibiting NF-κB activation in microglia cells
under LPS stimulation. Synaptamide-mediated inhibition
of microglia activation may not only serve as a new DHA-
derived neuroprotective mechanism but also provide a
potential therapeutic strategy for controlling neuroinflam-
mation and related neurodegenerative conditions.
Additional file
Additional file 1: Figure S1. Purity of microglia cells in culture assessed
by immunofluorescence detection of Iba-1- (microglia marker, red),
GFAP- (astrocyte marker, green), or O4-positive cells (oligodendrocyte
marker, green). The purity of the Iba-1-positive microglia was >90 %.
Figure S2. Dose- and time-dependent effect of LPS on TNF-α expression
in BV2 murine microglia cells. Cells were incubated with LPS (ng/mL) at
indicated concentration for 30 min, 1 h, and 4 h. Data are presented as
mean ± SEM (n = 3). The statistical significance was evaluated by Student’s
t test compared with control (CTL). Figure S3. Effect of synaptamide on
the plasma proinflammatory cytokines production in LPS-challenged
mice. C57BL/6 mice (n = 3 for each group) were treated with LPS
(1 mg/kg, i.p.) followed by synaptamide (5 mg/kg, i.p.), and blood was
collected at 2 and 6 h. Cytokine levels in the plasma were determine by
ELISA. Data are presented as mean ± SEM. The statistical significance was
evaluated by Student’s t test compared with the LPS treatment.
Figure S4. Suppression of LPS-induced IL-1β, IL-6, and CCL2 expression
specifically by synaptamide. BV2 cells were treated with LPS (100 ng/mL),
and 10 nM fatty acyl ethanolamides were added immediately after the
LPS exposure. Levels of IL-1β, IL-6, and CCL2 mRNA were determined by
qPCR after 1 h incubation. The data represent the mean ± SEM of three
independent experiments. The statistical significance was evaluated by
Student’s t test compared with the LPS treatment. (PPT 464 kb)
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